Stenotrophomonas maltophilia and Ventilator-Associated Pneumonia in Critically Ill Pediatric Patients: a Retrospective Analysis at a Single Center.
10.14776/piv.2015.22.2.75
- Author:
Byung Kee LEE
1
;
Soo Han CHOI
;
Soo Jin KIM
;
Joong Bum CHO
;
Hong AE
;
So Young YOO
;
Ji Hye KIM
;
Nam Young LEE
;
Yae Jean KIM
Author Information
1. Department of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea. yaejeankim@skku.edu
- Publication Type:Original Article
- Keywords:
Stenotrophomonas maltophilia;
Pneumonia;
Ventilator-Associated;
Child
- MeSH:
Anti-Infective Agents;
Child;
Critical Illness*;
Diagnosis;
Humans;
Korea;
Lung Diseases;
Male;
Mortality;
Pneumonia;
Pneumonia, Ventilator-Associated*;
Retrospective Studies*;
Seoul;
Stenotrophomonas maltophilia*;
Stenotrophomonas*;
Ventilators, Mechanical
- From:Pediatric Infection & Vaccine
2015;22(2):75-80
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Ventilator-associated pneumonia (VAP) is a serious threat in critically ill pediatric patients. Data regarding Stenotrophomonas maltophilia VAP in pediatric population is limited. We evaluated the clinical data of S. maltophilia associated VAP in critically ill pediatric patients. METHODS: A retrospective chart review was performed in pediatric patients 18 years old or younger who developed S. maltophilia associated VAP at Samsung Medical Center, Seoul Korea from January 2008 to December 2012. RESULTS: A total of 31 patients were identified S. maltophilia associated VAP. Median age was 8 months (range, 0.5 month to 16.6 years) and 13 patients were male (40.6%). Underlying illnesses were cardiologic diseases (n=11, 34.4%), hematologic oncologic malignancies (n=7, 25%), neurologic diseases (n=4, 12.5%), pulmonary diseases (n=3, 9.4%), and others (n=4, 12.5%). The median duration of ventilator use before S. maltophilia VAP diagnosis was 14 days (range, 4-256 days). Overall mortality at 30 days was 12.5% (4/32). CONCLUSIONS: S. maltophilia should be also considered as a possible pathogen for VAP in critically ill pediatric patients. Empiric antibiotic choice should include agents that are active against S. maltophilia in patients who are deteriorating on broad spectrum beta-lactam antimicrobial agents.
